DRKS00015729已完成不适用
A Post-Approval Registry of the TREO® Stent-Graft for Patients with Infrarenal Abdominal Aortic Aneurysms - TREO REGISTRY
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 138
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Age >18 years
- •Signed informed consent
- •Willingness to comply with study follow up
- •Indication for elective endovascular repair
- •Planned implantation of single TREOdevice system or aorto uni-iliac (AUI) device to include any auxilliary device components
排除标准
- •Intolerance to contrast media
- •emergency procedure
- •Chimneys or fenestrated device procedures
- •Connective tissue disease (e.g. Marfan's Syndrome)
- •high probability of non-adherence to physician's follow up requirements
- •Current participation in a concurrent trials that may confound study results
- •Female of childbearing potential in whom pregnancy cannot be excluded
- •Previous endovascular or surgical AAA repair
研究者
相似试验
招募中
不适用
Clinical safety evaluation of Endeavor stent in octogenerians.Coronary artery diseaseJPRN-UMIN000004138Cardiovascular center, Shinkawabashi hospital200
已完成
不适用
Retrospective Multicenter Registry of Stent Thrombosis After First- and Second-Generation Drug-Eluting Stents Implantatiocoronary artery diseaseJPRN-UMIN000025181Kokura Memorial Hospital1,300
已完成
4 期
The STARS-Trial: To Assess Stent Apposition by Optical Coherence Tomography (OCT) of the Svelte Sirolimus-Eluting Coronary Stent Systems (IDS and RX) Compared to the Abbott Vascular Xience Everolimus-Eluting Coronary Stent System for the Treatment of Atherosclerotic Lesions in a Randomized StudyatherosclerosisNL-OMON55040Amphia Ziekenhuis250
已完成
不适用
TRI-stent Adjudication Study - Low risk of RestenosisCoronary artery lesions with a low risk of restenosis undergoing percutaneous coronary treatmentCirculatory SystemOther disorders of arteries and arteriolesISRCTN47701105Academic Medical Centre (AMC) (Netherlands)1,260
招募中
2 期
Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung CancerJPRN-jRCT2080224062AbbVie GK35